BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2026 6:51:57 AM | Browse: 0 | Download: 0
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 126418
Country China
Received
2026-08-04 08:16
Peer-Review Started
2026-08-04 08:17
First Decision by Editorial Office Director
Return for Revision
2026-08-07 08:48
Revised
2026-08-14 09:24
Publication Fee Transferred
Editorial Processing by Scientific Editor
2026-10-15 03:35
Final Academic Decision by Editor-in-Chief
Publication Technical Verification by Editorial Office Director
2026-10-16 09:08
Articles in Press
2026-10-16 09:08
Edit the Manuscript by Language Editor
Typeset the Manuscript
2026-11-04 09:22
Publish the Manuscript Online
2026-11-19 06:51
ISSN 1948-5204 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Helicobacter pylori status in gastric cancer immunotherapy: Conflicting clinical associations, immune-microbial mechanisms, and biomarker challenges
Manuscript Source Invited Manuscript
All Author List Di Zhang, Shu-Han Li, Wei-Hao Zhang, Jun Weng, Ze-Hua Li and Kun-Hao Bai
ORCID
Author(s) ORCID Number
Ze-Hua Li http://orcid.org/0000-0001-5624-0087
Kun-Hao Bai http://orcid.org/0000-0003-1184-7576
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China No. 82403973
Corresponding Author Kun-Hao Bai, Associate Chief Physician, Associate Professor, MD, PhD, Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfengdong Street, Yuexiu District, Guangzhou 510060, Guangdong Province, China. baikh@sysucc.org.cn
Key Words Helicobacter pylori; Gastric cancer; Immune checkpoint inhibitors; Tumor immune microenvironment; Predictive biomarker
Core Tip Helicobacter pylori infection may influence gastric cancer immunotherapy outcomes, but clinical evidence remains conflicting – some studies associate positivity with poorer survival, others with enhanced benefit. This review examines the mechanistic pathways underlying this duality, including programmed cell death protein 1/programmed death-ligand 1 regulation, T-cell dysfunction, antigen presentation impairment, myeloid immunosuppression, and microbial ecological shifts. We propose that divergent findings reflect differences in infection definitions, detection methods, tumor subtypes, and treatment settings. Current evidence does not support Helicobacter pylori as a validated predictive biomarker; rather, it represents a context-dependent indicator of the tumor-immune-microbial background. Prospective studies with standardized infection definitions are critically needed.
Publish Date 2026-11-19 06:51
Citation

Zhang D, Li SH, Zhang WH, Weng J, Li ZH, Bai KH. Helicobacter pylori status in gastric cancer immunotherapy: Conflicting clinical associations, immune-microbial mechanisms, and biomarker challenges. World J Gastrointest Oncol 2026; 18(12): 126418

URL https://www.wjgnet.com/1948-5204/full/v18/i12/126418.htm
DOI https://doi.org/10.4251/wjgo.126418
Full Article (PDF) WJGO-18-126418-with-cover.pdf